stockportfolio.pro
Absci Corporation (ABSI)
Healthcare · Biotechnology · NasdaqGS
Absci Corporation revenue & earnings — last 6 fiscal years
| Metric | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | $4.78M | $4.78M | $5.75M | $5.72M | $4.53M | $2.80M |
| Gross profit | — | — | — | — | — | — |
| Net income | $-14.35M | $-100.96M | $-104.90M | $-110.57M | $-103.11M | $-115.18M |
| Net margin | -300.3% | -2111.3% | -1825.4% | -1933.6% | -2274.1% | -4113.7% |
Source: Absci Corporation SEC filings (10-K).
Explore 6 years of Absci Corporation financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track ABSI in your portfolio →
Absci Corporation financial history by metric
About Absci Corporation
Absci Corporation, a clinical-stage biopharmaceutical company, develops various antibody therapeutics in the United States. Its preclinical development programs include ABS-101, which is in Phase 1 clinical trial for the treatment of inflammatory bowel disease; ABS-201, an anti-prolactin receptor (PRLR) antibody, which is phase 1/2a clinical trial for treating androgenic alopecia; ABS-301 for the treatment of immuno-oncology; and ABS-501 for treating oncology. Absci Corporation has collaboration agreements with PrecisionLife, Memorial Sloan Kettering Cancer Center, Twist Bioscience, Owkin, Oracle Corporation, and Advanced Micro Devices, Inc. for joint research and development activities. The company was founded in 2011 and is headquartered in Vancouver, Washington.
Absci Corporation — frequently asked questions
What is Absci Corporation's revenue?
Absci Corporation (ABSI) reported revenue of $2.80M for fiscal year 2025, down 38.2% from the prior year, according to its SEC filings.
Is Absci Corporation profitable?
No — ABSI reported a net loss of $-115.18M in fiscal 2025.
What is ABSI's P/E ratio?
Absci Corporation trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How fast is Absci Corporation growing?
ABSI's revenue grew at roughly -10.1% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
How much debt does Absci Corporation have?
As of fiscal year 2025, ABSI carried roughly $873,000 in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Absci Corporation's market cap?
Absci Corporation (ABSI) has a market capitalization of about $986.88M, based on the latest data in our nightly-refreshed cache.
When does Absci Corporation's fiscal year end?
ABSI's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
Where does this data come from?
All figures are computed from Absci Corporation's official SEC filings (10-K and 10-Q), covering 6 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.